Prognostic and predictive factors in prostate cancer

Cancer Treatment Reviews

Volumn 27, Issue 3, 2001, Pages 143-151

  Hamdy, F C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EUROPE; EUROPEAN UNION; HEALTH CARE SYSTEM; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PHYSICIAN; PREDICTION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PUBLIC HEALTH; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES; WESTERN HEMISPHERE;

EID: 0035015525     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0208     Document Type: Article

References (42)

1. Møller Jensen O., Estève J., Møller H., Renard H. Cancer in the European community and its member states. Eur J Cancer. 26:1990;1167-1256.
2. Wei J., Gravlin K., Cooney K. A. Osteoporosis after orchidectomy for prostate cancer. J Urol. 150:1998;1809.
3. Partin A. W., Yoo J. K., Carter H. B. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with prostate cancer. J Urol. 150:1993;110.
4. Ackerman D. A., Barry J. M., Wicklund R. A., Olson N., Lowe B. A. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol. 150:1993;1845-1850.
5. Wills M. L., Sauvageot J., Partin A. W., Gurganus R., Epstein J. I. Ability of sextant biopsies to predict radical prostatectomy stage. Urology. 51:1998;759-764.
6. Li W., Ren Y., Mee V., Wong P. Y. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin Biochem. 62:1999;31-37.
7. Partin A. W., Kattan M. W., Subong E. N. P. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. J Am Med Assoc. 277:1997;1445-1451.
8. Epstein J. I., Carmichael M. J., Pizov G., Walsh P. C. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up. J Urol. 150:1993;135-141.
9. Pettaway C. A. Prognostic markers in clinically localised prostate cancer. Techniques in Urology. 1:1998;35-42.
10. Cooper E. H., Wheelan P., Purves D. Bone alkaline phosphatase and prostate-specific antigen in monitoring of prostate cancer. Prostate. 25:1994;236-240.
11. Lorente J. A., Valuenzuela H., Morote J., Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med. 26:1999;625-632.
12. Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 157:1997;539-543.
13. Hamdy F. C., Lawry J., Anderson J. B., Parsons M. A., Rees R. C., Williams J. L. Circulating prostate-specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol. 69:1992;392-396.
14. Fadlon E. J., Rees R. C., Lawry J., McIntyre C., Sharrard M., Hamdy F. C. Detection of circulating PSA-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Br J Cancer. 74:1996;400-405.
15. Katz A. E., Olsson C. A., Raffo A. J. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 43:1994;765-774.
16. De la Taille A., Olsson C., Katz A. E. Molecular staging of prostate cancer: dream or reality? Oncology. 13:1999;187-194.
17. Ylikoski A., Boeken Kruger A., Trapman J. Multicentre validation of quantitative RT-PCR assay for detection of prostate specific antigen mRNA. Eur Urol. 35:1999;97.
18. Apakama I., Robinson M. C., Walter N. M. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer. 74:1996;1258-1262.
19. Johnson M. I., Robinson M. C., Marsh C., Robson C. N., Neal D. E., Hamdy F. C. Expression of bcl-2, bax and p53 in high grade PIN and localized prostate cancer: relationship with apoptosis and proliferation. Prostate. 37:1998;223-229.
20. Moul J. W., Bettencourt M-C., Sesterhenn I. A. Protein expression of p53, bcl-2 and KI-67 (MIB-1) as prognostic biomarkers; in patients with surgically treated, clinically localized, prostate cancer. Surgery. 120:1996;159-166.
21. Visakorpi T. New pieces to the prostate cancer puzzle. Nature Med. 5:1999;264-265.
22. Kadkol S. S., Brody J. R., Pevsner J., Pai J., Pasternack G. R. Modulation of oncogenic potential by alternative gene usage in human prostate cancer. Nature Med. 5:1999;275-279.
23. Silberman M. A., Partin A. W., Veltri R. W., Epstein J. I. Tumour angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 79:1997;772-779.
24. Ferrer F. A., Miller L. J., Andrawis R. I. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 157:1997;2329-2333.
25. Byrne R. L., Leung H., Neal D. E. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol. 77:1996;627-633.
26. Hamdy F. C., Autzen P., Wilson Horne C. H., Robinson M. C., Neal D. E., Robson C. N. Immunolocalization and mRNA expression of bone morphogenetic protein-6 in human benign and malignant prostate tissue. Cancer Res. 57:1997;4427-4431.
27. Johnson M., Autzen P., Robson C. Prognostic value of bone morphogenetic protein-6 expression in clinically organ- confined prostate cancer. Eur Urol. 35:1999;128.
28. Story M. T. Regulation of prostate growth by fibroblast growth factors. World J Urol. 13:1995;297-305.
29. Leung H. Y., Mehta P., Gray L. B., Collins A. T., Robson C. N., Neal D. E. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene. 15:1997;1115-1120.
30. Jones J. I., Clemmons D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev. 16:1995;3-34.
31. Kanety H., Madjar Y., Dagan Y. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrin Metab. 77:1993;229-233.
32. Denmeade S. R., Lin X. S., Isaacs J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 28:1996;251-265.
33. Craft N., Shostak Y., Carey M., Sawyers S. L. A mechanism for hormone independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nature Med. 5:1999;280-285.
34. Adler H. L., McCurdy M. A., Kattan M. W., Timme T. L., Scardino P. T., Thompson T. C. Elevated levels of circulating IL-6 and TGF-E1 in patients with metastatic prostatic carcinoma. J Urol. 161:1999;182-187.
35. Waltregny D., Bellahcène A., Van Riet I. Prognostic value of bone sialoprotein expression in clinically localised human prostate cancer. J Natl Cancer Inst. 90:1998;1000-1008.
36. Umbas R., Isaacs W. B., Bringuier P. B. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54:1994;3929-3933.
37. Kallakury B. V. S., Yang F., Figge J. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer. 78:1996;1461-1469.
38. Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results. Int J Cancer. 58:1994;211-216.
39. Carter B. S., Beaty T. H., Steinberg G. D., Childs B., Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc Nat Acad Sci USA. 89:1992;3367-3371.
40. Hamdy F. C., Fadlon E. J., Cottam D. W. Matrix metalloproteinase-9 expression in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer. 69:1994;177-182.
41. Still K., Robson C. N., Autzen P., Robinson M. C., Hamdy F. C. Localisation and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate. 42:2000;18-25.
42. Daniell H. W. Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:1997;439-444.